Breast Cancer Screening

Clinical meaning

Breast cancer arises from the malignant transformation of mammary epithelial cells through the accumulation of genetic and epigenetic alterations affecting oncogenes and tumor suppressor genes. Understanding molecular subtypes is essential for advanced prescriptive management and screening risk stratification.

Molecular subtypes are classified by gene expression profiling into four clinically actionable categories. Luminal A (ER+/PR+/HER2-/low Ki-67) is the most common (40-50%), driven by estrogen receptor alpha (ERα) transcriptional activation of cell proliferation genes. These tumors have the best prognosis and respond to endocrine therapy. Luminal B (ER+/PR+/-/HER2+/-/high Ki-67) has higher proliferative index and poorer prognosis than Luminal A. HER2-enriched (ER-/PR-/HER2+) tumors overexpress human epidermal growth factor receptor 2 (HER2/ERBB2) through gene amplification on chromosome 17q12, causing constitutive activation of the RAS-MAPK and PI3K/AKT proliferation cascades. Triple-negative breast cancer (TNBC - ER-/PR-/HER2-) lacks all three receptors, is highly proliferative, and disproportionately affects BRCA1 mutation carriers and young African American women.

Hereditary breast cancer accounts for 5-10% of all breast cancers. BRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12.3) are tumor suppressor genes encoding proteins essential for homologous recombination repair (HRR) of double-strand DNA breaks. Loss-of-function mutations impair DNA repair fidelity, leading to genomic instability and cancer predisposition. BRCA1 carriers have 60-80% lifetime breast cancer risk and 40-60% ovarian cancer risk. BRCA2 carriers have 45-70% lifetime breast cancer risk and 15-25% ovarian cancer risk.

Risk assessment models guide screening intensity. The Gail model calculates 5-year and lifetime risk using age, menarche, first live birth, prior biopsies, atypia, and first-degree relatives - it underestimates risk in women with strong paternal family history or known genetic mutations. The Tyrer-Cuzick (IBIS) model is more comprehensive, incorporating second-degree family history, BRCA status, breast density, BMI, and hormone use - recommended by NCCN for risk stratification. Lifetime risk ≥20% qualifies for supplemental screening with breast MRI.

Your next step on CNPLE

Stay on Advanced practice—questions and lessons stay exam-scoped so you are not mixing tracks.

Diagnosis & workup

Diagnostics & workup: - Order screening mammography - USPSTF recommends biennial screening ages 50-74 (2024 update: consider starting at 40); ACR/NCCN recommend annual screening starting at 40 for average risk - Order breast MRI with gadolinium contrast for high-risk patients (lifetime risk ≥20% by Tyrer-Cuzick model) - annual MRI alternating with mammography every 6 months - Calculate lifetime breast cancer risk using Tyrer-Cuzick (IBIS) model - most comprehensive validated risk calculator incorporating genetics, family history, density, and hormonal factors - Assess breast density on mammography (ACR BI-RADS density categories A-D) - dense breasts (C/D) reduce mammographic sensitivity from 85% to 48-64% and independently increase cancer risk 1.5-2 fold - Order supplemental screening ultrasound for dense breasts when MRI is not indicated or available - Refer for genetic counseling and BRCA1/BRCA2 testing when family history meets NCCN criteria - triple-negative breast cancer <60 years, Ashkenazi Jewish heritage, male breast cancer, breast + ovarian cancer in family - Perform clinical breast exam (CBE) at screening visits - palpate all four quadrants, axillary and supraclavicular lymph nodes - Order diagnostic mammography with spot compression and magnification views for palpable masses or screening abnormalities - Order core needle biopsy (ultrasound-guided or stereotactic) for BI-RADS 4 or 5 lesions - histologic diagnosis before any treatment planning - Consider contrast-enhanced mammography (CEM) as alternative to MRI for high-risk screening when MRI is contraindicated or unavailable

Risk factors: - BRCA1/BRCA2 mutation carrier (highest risk - 60-80% lifetime risk for BRCA1) - First-degree relative with breast cancer (especially premenopausal diagnosis) - Prior chest radiation (age 10-30 - Hodgkin lymphoma treatment) - Atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS) on prior biopsy - Mammographically dense breast tissue (category C or D - masks tumors and independently increases risk) - Early menarche (<12) or late menopause (>55) - prolonged estrogen exposure - Nulliparity or first live birth after age 30 - Obesity in postmenopausal women (increased peripheral aromatase activity in adipose tissue) - Combined hormone replacement therapy (estrogen + progestin > 5 years) - Li-Fraumeni syndrome (TP53 mutation), Cowden syndrome (PTEN mutation), or other high-penetrance cancer predisposition syndromes

Clinical meaning

Your next step on CNPLE

Practice this topic

Review related lessons

CNPLE CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on CNPLE

Practice this topic

Review related lessons

CNPLE CAT

Clinical meaning

Practice questions for this topic

Your next step on CNPLE

Practice this topic

Review related lessons

CNPLE CAT

Diagnosis & workup

Practice questions for this topic

Your next step on CNPLE

Practice this topic

Review related lessons

CNPLE CAT